.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,846,718

« Back to Dashboard

Claims for Patent: 8,846,718

Title:Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
Abstract: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.
Inventor(s): Keshavarz-Shokri; Ali (San Diego, CA), Zhang; Beili (San Diego, CA), Krawiec; Mariusz (Marlborough, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:13/933,223
Patent Claims: 1. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl)benzoic acid characterized as Form I, wherein the mammal has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence.

2. The method of claim 1, wherein the mammal has two copies of the defective gene.

3. The method of claim 1, wherein the Form I is characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.

4. The method of claim 3, wherein the Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees.

5. The method of claim 3, wherein the Form I is further characterized by a peak at 14.6 to 15.0 degrees.

6. The method of claim 5, wherein the Form I is further characterized by a peak at 14.8 degrees.

7. The method of claim 5, wherein the Form I is further characterized by a peak at 17.6 to 18.0 degrees.

8. The method of claim 7, wherein the Form I is further characterized by a peak at 17.8 degrees.

9. The method of claim 7, wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees.

10. The method of claim 9, wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees.

11. The method of claim 10, wherein the Form I is further characterized by a peak at 16.6 degrees.

12. The method of claim 10, wherein the Form I is further characterized by a peak at 7.6 to 8.0 degrees.

13. The method of claim 12, wherein the Form I is further characterized by a peak at 7.8 degrees.

14. The method of claim 12, wherein the Form I is further characterized by a peak at 25.8 to 26.2 degrees.

15. The method of claim 14, wherein the Form I is further characterized by a peak at 26.0 degrees.

16. The method of claim 14, wherein the Form I is further characterized by a peak at 21.4 to 21.8 degrees.

17. The method of claim 16, wherein the Form I is further characterized by a peak at 21.6 degrees.

18. The method of claim 16, wherein the Form I is further characterized by a peak at 23.1 to 23.5 degrees.

19. The method of claim 18, wherein the Form I is further characterized by a peak at 23.3 degrees.

20. The method of claim 1, wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 1.

21. The method of claim 1, wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 2.

22. The method of claim 1, wherein the particle size distribution of D90 is about 82 .mu.m or less.

23. The method of claim 1, wherein the particle size distribution of D50 is about 30 .mu.m or less.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc